| DC Field | Value | Language |
|---|
| dc.contributor.author | Pokrovskiy, M. V. | - |
| dc.contributor.author | Korokin, M. V. | - |
| dc.contributor.author | Tsepeleva, S. A. | - |
| dc.contributor.author | Pokrovskaya, T. G. | - |
| dc.contributor.author | Kochkarov, V. I. | - |
| dc.date.accessioned | 2013-05-13T11:11:57Z | - |
| dc.date.available | 2013-05-13T11:11:57Z | - |
| dc.date.issued | 2011 | - |
| dc.identifier.citation | Arginase inhibitor in the pharmacological correction of endothelial dysfunction / M.V. Pokrovskiy, ... T.G. Pokrovskaya, ... V.I. Kochkarov et al. ; Belgorod State University // International journal of hypertension. - 2011. - Vol.2011.-Art. 515047. - doi: 10.4061/2011/515047. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/4629 | - |
| dc.description.abstract | This paper is about a way of correction of endothelial dysfunction with the inhibitor of arginase: L-norvaline. There is an imbalance between vasoconstriction and vasodilatation factors of endothelium on the basis of endothelial dysfunction. Among vasodilatation agents, nitrogen oxide plays the basic role | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | internal medicine | ru |
| dc.subject | heart disease | ru |
| dc.subject | cardiology | ru |
| dc.subject | arterial hypertension | ru |
| dc.subject | endothelium | ru |
| dc.subject | endothelial dysfunction | ru |
| dc.title | Arginase inhibitor in the pharmacological correction of endothelial dysfunction | ru |
| dc.type | Article | ru |
| dc.identifier.citationpublication | International journal of hypertension | ru |
| dc.identifier.citationvolume | 2011 | ru |
| dc.identifier.citationfirstpage | 515047 | ru |
| dc.description.refereed | yes | ru |
| dc.description.institution | Belgorod State University | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
